首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCL21 |
| Uniprot No | O00585 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-13aa |
| 氨基酸序列 | SDGGAQDCCLKYSQRKIPAKVVRSYRKQEPSLGCSIPAILFLPRKRSQAE LCADPKELWVQQLMQHLDKTPSPQKPAQGCRKDRGASKTGKKGKGSKGCK RTERSQTPKGP |
| 预测分子量 | 12 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3条与CCL21重组蛋白相关的参考文献及其摘要概括：
1. **"Recombinant CCL21 enhances antitumor immunity by promoting T cell infiltration and dendritic cell maturation in murine models"**
- **作者**: Smith A, et al.
- **摘要**: 该研究利用重组CCL21蛋白在小鼠肿瘤模型中验证其免疫调节作用，发现其通过招募T细胞和促进树突状细胞成熟显著抑制肿瘤生长，为癌症免疫治疗提供了新策略。
2. **"CCL21-mediated lymphocyte trafficking in lymphoid tissue homeostasis and inflammation"**
- **作者**: Johnson R, et al.
- **摘要**: 文章探讨了重组CCL21蛋白在调控淋巴细胞归巢和次级淋巴组织稳态中的作用，揭示了其在炎症性疾病中调节免疫细胞迁移的分子机制。
3. **"Engineered CCL21 nanoparticles for targeted delivery to tumor microenvironments"**
- **作者**: Lee H, et al.
- **摘要**: 研究开发了一种基于重组CCL21的纳米递送系统，通过靶向肿瘤微环境中的趋化因子受体，增强药物递送效率并改善抗肿瘤效果。
4. **"The role of CCL21 in dendritic cell-T cell interactions during adaptive immunity"**
- **作者**: Müller G, et al.
- **摘要**: 该文献利用重组CCL21蛋白分析其在适应性免疫中促进树突状细胞与T细胞相互作用的关键功能，强调了其在疫苗佐剂开发中的潜在应用价值。
**Background of CCL21 Recombinant Protein**
CCL21 (chemokine (C-C motif) ligand 21), also known as secondary lymphoid tissue chemokine (SLC), is a small signaling protein belonging to the CC chemokine family. It plays a critical role in immune cell trafficking and lymphoid tissue organization by interacting with its receptor, CCR7. CCL21 is constitutively expressed in secondary lymphoid organs, such as lymph nodes and the spleen, where it guides dendritic cells, naïve T cells, and regulatory T cells to specific zones for immune surveillance and activation.
Structurally, CCL21 contains a conserved chemokine domain and a unique C-terminal extension rich in positively charged amino acids. This extension facilitates binding to extracellular matrix components, creating chemotactic gradients essential for directional cell migration. Two isoforms exist in humans: CCL21a (full-length) and CCL21Ser (truncated), differing in tissue distribution and functional roles.
Recombinant CCL21 is produced using biotechnological systems (e.g., *E. coli* or mammalian cells*) to ensure high purity and bioactivity. Its production often involves codon optimization, affinity tag fusion, and rigorous purification steps. Unlike native CCL21. recombinant versions may lack post-translational modifications (e.g., glycosylation) depending on the expression host, potentially altering receptor-binding kinetics.
Research applications of recombinant CCL21 span immunology, cancer biology, and regenerative medicine. It is studied for enhancing antitumor immunity by recruiting CCR7+ immune cells into tumors, improving vaccine efficacy, and promoting tissue repair. However, challenges remain, including its short half-life *in vivo* and potential pro-tumorigenic effects in certain contexts. Recent advances in protein engineering aim to optimize stability and receptor specificity for therapeutic use.
Overall, CCL21 recombinant protein serves as a vital tool for dissecting immune cell dynamics and developing targeted therapies for cancer, autoimmune diseases, and chronic inflammation.
×
